, /PRNewswire/ -- a clinical-stage radiopharmaceutical company, today announced that they have entered into a collaboration and licensing-agreement with the Medical University of Innsbruck (MUI), a leading European research institution to advance the development of novel radiopharmaceuticals. The agreement covers the clinical development of EVG321, a novel radioligand therapy (RLT) for small cell lung cancer (SCLC), targeting the cholecystokinin 2 receptor (CCK2R). RLTs have surged into the clinic and represent a rapidly expanding market.
By combining the power of medical isotopes and the precision of targeted therapeutics, these types of medicines allow for cell-specific ablation of a tumor target, thereby localizing ionizing radiation to diseased tissues. CCK2R has been shown to be highly expressed in SCLC, and has the potential to facilitate robust, tumor-specific delivery. " ," commented , CEO of Evergreen Theragnostics.
" ." He added: " Univ. Prof.
Dr. Irene Virgolini, Medical University of Innsbruck, said: " Over the next months, Evergreen intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 ( Lu) EVG321 and Gallium-68 ( Ga) EVG321. If successful, EVG321 could offer new hope to patients with small cell lung cancer.
Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as dru.
